ArticleCancer immunology, immunotherapy : CII2016

Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells.

Toshiko Kamata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.